医生介绍
· Male
· Multidisciplinary Team(s)
· Hematologic (Malignant)
· Department/Research Program(s)
· Department of Oncology
· Cancer Type(s)
· Multiple Myeloma
Amyloidosis
Non-Hodgkin's Lymphoma
Leukemia
Plasmacytoma
· Contact Info
· Email:
zonderj@karmanos.org
来自 <http://www.karmanos.org/physicians/Jeffrey-Zonder?Disease=73&PageIndex=0&SortDirection=1>
· Education
· Fellowship
Hematology/oncology Fellow, Wayne State University, Detroit Medical Center, Detroit, MI
Fellowship
Hematology/oncology Chief Fellow, Wayne State University, Detroit Medical Center, Detroit, MI
Medical School
Wayne State University School of Medicine
1995
Residency
Primary Care Internal Medicine Residency Program, Strong Memorial Hospital, Rochester, NY
1998
· Professional Memberships/Associations
· American Society of Hematology
American Society of Clinical Oncology
Southwest oncology Group, Multiple Myeloma and Special Populations Committees
· Board Certifications
· Michigan State and New York State License
American Board of Internal Medicine
American Board of Internal Medicine - Oncology
· Clinical Interests
· Hematology Oncology
· Research Interests
· Investigation of new drug application for white cell disorders
· Profile
· Dr. Zonder has special interest in multidisciplinary care of patients with Multiple Myeloma, as well as other hematologic cancers.In addition, he is focused on the investigation of therapies for Multiple Myeloma.
· Awards
· 2007 Wayne State University Division of Hematology-Oncology, Hematology Teaching Attending of the Year
2005 Teaching Award, Wayne State University School of Medicine
· Publications
· A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma.Blood. 2011 Dec 19. [Epub ahead of print] Authors: Zonder JA, Mohrbacher AF, Singhal S, van Rhee F, Bensinger WI, Ding H, Fry J, Afar DE, Singhal AK
Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial.J Clin Oncol. 2011 Nov 10;29(32):4243-9. Epub 2011 Oct 11. Authors: Richardson PG, Wolf J, Jakubowiak A, Zonder J, Lonial S, Irwin D, Densmore J, Krishnan A, Raje N, Bar M, Martin T, Schlossman R, Ghobrial IM, Munshi N, Laubach J, Allerton J, Hideshima T, Colson K, Poradosu E, Gardner L, Sportelli P, Anderson KC.
Dermatological complications following initiation of lenalidomide in a patient with chronic lymphocytic leukaemia. Intern Med J. 2011 Mar;41(3):286-8. doi: 10.1111/j.1445-5994.2011.02426.x. Authors: Tageja N, Giorgadze T, Zonder J.
Cancer Patient Fracture evaluation (CAFE) Investigators.Balloon kyphoplasty versus non-surgical fracture management for treatment of painful vertebral body compression fractures in patients with cancer: a multicentre, randomised controlled trial. Lancet Oncol. 2011 Mar;12(3):225-35. Epub 2011 Feb 16. Authors: Berenson J, Pflugmacher R, Jarzem P, Zonder J, Schechtman K, Tillman JB, Bastian L, Ashraf T, Vrionis F;
Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: a reandomized Southwest oncology Group trial (S0232). Blood. 2010 Dec 23;116(26):5838-41. Epub 2010 Sep 27. Authors: Zonder JA, Crowlet J, Hussein MA, Bolejack V, Moore DF Sr, Whittenberger BF, Abidi MH, Durie BG, Barlogie B.
相关报道资讯
视频科普
-
-
【3月12日】肿瘤患者怎样避免人财两空？
简介：... 更多»
-
-
肿瘤临床试验患者真实采访（下）患者谈：临床试验是小白鼠吗？
简介：... 更多»
-
-
肿瘤临床试验患者真实采访（上）临床试验带来的希望
简介：... 更多»
-
-
胃癌IV期伴有肝脏及肝胃间隙淋巴结转移患者赴日就医
简介： 胃癌IV期伴有肝脏及肝胃间隙淋巴结转移，国内无标准方案，会诊得知这里胃癌5年生存率相比要高。习惯了家里的医院，还真不适应... 更多»
-
-
大肠癌伴肝转移患者赴日就医
简介：大肠癌伴肝转移，本想国内治疗，但通过日ben癌研有明医院在线会诊，家人支持来院手术。非常顺利4小时完成切除和淋巴结清扫，第二... 更多»
-
-
胶质母细胞瘤和髓母细胞瘤患者赴日就医
简介： 你经历过绝望到希望吗？在国内先后被诊断为胶质母细胞瘤和髓母细胞瘤的患者。术后只做了脑部放疗，复发了。最后参加了日ben国... 更多»
-
-
肝癌患者日本国际就医案例
简介： 肝癌，多年前在日ben癌研有明病院做的手术，这次来复查，结果很满意，但是还需3个月后再次复查，6月份再来，明日回国，感谢帮... 更多»
-
-
癌症患者的新方案来了！数十位国际专家带先进技术助力国内癌症患者
简介：癌症患者的新方案来了！数十位国际专家带先进技术助力国内癌症患者... 更多»
首页
咨询
方舟新药
营养商城